Prostate cancer


Prostate cancer is a type of malignancy that arises in the prostate gland. Prostate cancer tends to develop in older men, aged 50 and over. In many cases prostate cancer develops slowly, although in some cases it can be aggressive and metastasize to other parts of the body.


Latest Research and Reviews

  • Research | | open

    In prostate cancer, the role of mutations in the maternally-inherited mitochondrial genome are not well known. Here, the authors demonstrate frequent, age-dependent mitochondrial mutation in prostate cancer. Strong links between mitochondrial and nuclear mutational profiles are associated with clinical aggressivity.

    • Julia F. Hopkins
    • , Veronica Y. Sabelnykova
    • , Joachim Weischenfeldt
    • , Ronald Simon
    • , Jennifer A. Aguiar
    • , Rached Alkallas
    • , Lawrence E. Heisler
    • , Junyan Zhang
    • , John D. Watson
    • , Melvin L. K. Chua
    • , Michael Fraser
    • , Francesco Favero
    • , Chris Lawerenz
    • , Christoph Plass
    • , Guido Sauter
    • , John D. McPherson
    • , Theodorus Kwast
    • , Jan Korbel
    • , Thorsten Schlomm
    • , Robert G. Bristow
    •  & Paul C. Boutros
  • Reviews |

    WNT signalling pathway components are potentially important in prostate tumours, particularly in the development of castration-resistant prostate cancer and in the prostate tumour microenvironment. Here, Murillo-Garzón and Kypta describe our current understanding of WNT signalling in prostate cancer and discuss the potential of drugs that target this pathway.

    • Virginia Murillo-Garzón
    •  & Robert Kypta
  • Reviews |

    Prostate cancer biology seems to be distinct among men of different ethnicities and races, as demonstrated by remarkable differences in the frequency of ERG oncogenic activation. In this Review, Sedarsky and colleagues discuss worldwide ERG alteration frequencies and consider how the data can be affected by variations in assay platforms and specimen types, as well as ethnic and geographical classifications, in order to realize the potential of precision medicine for men with prostate cancer.

    • Jason Sedarsky
    • , Michael Degon
    • , Shiv Srivastava
    •  & Albert Dobi

News and Comment